PTC Therapeutics ( (PTCT) ) has provided an announcement.
PTC Therapeutics reported robust financial results for Q3 2024, with total revenues reaching $197 million. The company raised its full-year revenue guidance to $750-800 million, driven by strong sales from its DMD franchise and continued regulatory progress. PTC’s strategic focus on high-potential R&D programs is evident, with multiple FDA submissions accepted for review and plans for additional filings. Despite a net loss of $106.7 million, PTC is well-positioned financially with over $1 billion in cash and equivalents.
For a thorough assessment of PTCT stock, go to TipRanks’ Stock Analysis page.
